Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ECOLAB INC.ECL · Entity 2954 | Director | September 30, 2026 | October 03, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director · President, CEO and Board Chair | March 01, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ECOLAB INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,089.19 |
Reported balance
After 2026-09-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 131.17 · Balance 8,089.19 F1: Includes 10.74 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. |
| Common StockSEC Table I · non-derivative | Direct | 8,233.94 |
Reported balance
After 2026-09-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-30 · Grant · Acquired 144.75 · Balance 8,233.94 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 10.74 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan.
WEST PHARMACEUTICAL SERVICES INC
Report date March 01, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 6,986 |
Reported balance
After 2026-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-01 · Grant · Acquired 6,986 · Balance 6,986 F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $254.34 · Expires 2036-03-01 | Direct | 16,630 |
Reported balance
After 2026-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-01 · Grant · Acquired 16,630 · Balance 16,630 F3: The stock option vests in four equal annual installments beginning on March 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock.
F2: The restricted stock units vest in four equal annual installments beginning on March 1, 2027.
F3: The stock option vests in four equal annual installments beginning on March 1, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:48 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 144.75 | $276.36 | $40,002.39 |
DisclosureSEC source: 0001628280-26-064591 · wk-form4_1790974081.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,233.94 Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:48 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 131.17 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-064591 · wk-form4_1790974081.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,089.19 F1 · balance_after: Includes 10.74 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| September 11, 2026 Filed Sep 14, 2026 20:35 UTC | ECOLAB INC. ECL · Entity 2954 | PurchaseCommon Stock | 320 | $277.29 | $88,733.12 |
DisclosureSEC source: 0001628280-26-061859 · wk-form4_1789418117.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,947.28 F2 · price: This transaction was executed in multiple trades at prices ranging from $277.120 to $277.410, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2026 Filed Sep 14, 2026 20:35 UTC | ECOLAB INC. ECL · Entity 2954 | PurchaseCommon Stock | 3,370 | $276.58 | $932,064.49 |
DisclosureSEC source: 0001628280-26-061859 · wk-form4_1789418117.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,627.28 F1 · price: This transaction was executed in multiple trades at prices ranging from $276.370 to $276.890, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:35 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 143.65 | $278.46 | $40,000.49 |
DisclosureSEC source: 0001336007-26-000008 · form4-07022026_080723.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,257.28 Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:35 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 130.18 | $0.00 | $0.00 |
DisclosureSEC source: 0001336007-26-000008 · form4-07022026_080723.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,113.63 F1 · balance_after: Includes 9.94 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:59 UTC | ECOLAB INC. ECL · Entity 2954 | GrantNon-Employee Director Stock Option (Right to Buy) · Derivative | 732 | $0.00 Strike: $247.70 | $0.00 |
DisclosureSEC source: 0001336007-26-000006 · form4-05192026_080552.xml · derivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732 Underlying: Common Stock · 732 shares Expires 2036-05-15 F1 · derivative.exercise_date: The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the earlier of the last day of the fourth three-month period following its date of grant or the company's next annual meeting date; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full. The date listed in the Date Exercisable column represents the first vesting date. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:59 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 152.07 | $263.03 | $39,998.97 |
DisclosureSEC source: 0001336007-26-000004 · form4-04022026_080444.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,973.51 Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:59 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 137.82 | $0.00 | $0.00 |
DisclosureSEC source: 0001336007-26-000004 · form4-04022026_080444.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,821.44 F1 · balance_after: Includes 8.96 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 16:33 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 16,630 | $0.00 Strike: $254.34 | $0.00 |
DisclosureSEC source: 0000105770-26-000038 · form4.xml · derivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,630 Underlying: Common Stock · 16,630 shares Expires 2036-03-01 F3 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on March 1, 2027. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 16:33 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 6,986 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000038 · form4.xml · derivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,986 Underlying: Common Stock · 6,986 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionRst. Stock Unit · Derivative | 1,318.81 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000017 · form4.xml · derivative · entry 6 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,956.409 Underlying: Common Stock · 1,318.81 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 18, 2025, the reporting person was granted 5,256 restricted stock units, vesting in four equal annual installments (plus dividend equivalents). F3 · derivative.expiration_date: On February 18, 2025, the reporting person was granted 5,256 restricted stock units, vesting in four equal annual installments (plus dividend equivalents). Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 573.551 | $248.26 | $142,389.77 |
DisclosureSEC source: 0000105770-26-000017 · form4.xml · nonDerivative · entry 4 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,160.6588 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 00:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 1,318.81 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000105770-26-000017 · form4.xml · nonDerivative · entry 3 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,734.2098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 00:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 1,305.382 | $243.19 | $317,455.85 |
DisclosureSEC source: 0000105770-26-000017 · form4.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,894.6085 Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 00:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 4,418.771 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000017 · form4.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,199.9905 F1 · shares: These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:46 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 137.48 | $263.68 | $36,250.04 |
DisclosureSEC source: 0001336007-26-000002 · form4-01052026_090154.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,674.66 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:46 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 128 | $0.00 | $0.00 |
DisclosureSEC source: 0001336007-26-000002 · form4-01052026_090154.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,537.18 F1 · balance_after: Includes 7.47 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:38 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 132.37 | $273.87 | $36,252.17 |
DisclosureSEC source: 0001336007-25-000006 · form4-10022025_081009.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,401.71 Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:38 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 123.23 | $0.00 | $0.00 |
DisclosureSEC source: 0001336007-25-000006 · form4-10022025_081009.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,269.34 F1 · balance_after: Includes 7.02 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:41 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 135.52 | $267.48 | $36,248.89 |
DisclosureSEC source: 0001415889-25-019079 · form4-07022025_080712.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,139.09 Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:41 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 126.18 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019079 · form4-07022025_080712.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,003.57 F1 · balance_after: Includes 7.06 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| May 12, 2025 Filed May 14, 2025 20:52 UTC | ECOLAB INC. ECL · Entity 2954 | GrantNon-Employee Director Stock Option (Right to Buy) · Derivative | 810 | $0.00 Strike: $255.76 | $0.00 |
DisclosureSEC source: 0001415889-25-012893 · form4-05142025_080556.xml · derivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 810 Underlying: Common Stock · 810 shares Expires 2035-05-12 F1 · derivative.exercise_date: The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full. The date listed in the Date Exercisable column represents the first vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:56 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 144.1 | $251.56 | $36,250.08 |
DisclosureSEC source: 0001415889-25-009682 · form4-04022025_080429.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,870.33 Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:56 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 134.16 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009682 · form4-04022025_080429.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,726.23 F1 · balance_after: Includes 6.28 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 5,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006115 · form4.xml · derivative · entry 4 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,256 Underlying: Common Stock · 5,256 shares Expires not disclosed F1 · derivative.exercise_date: This award vests in four equal installments beginning on February 18, 2026. F1 · derivative.expiration_date: This award vests in four equal installments beginning on February 18, 2026. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 12,149 | $0.00 Strike: $211.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006115 · form4.xml · derivative · entry 3 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,149 Underlying: Common Stock · 12,149 shares Expires 2035-02-18 F1 · derivative.exercise_date: This award vests in four equal installments beginning on February 18, 2026. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 700.296 | $211.00 | $147,762.46 |
DisclosureSEC source: 0001127602-25-006115 · form4.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,668.8195 Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 2,460.991 | $211.00 | $519,269.10 |
DisclosureSEC source: 0001127602-25-006115 · form4.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,369.1155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:04 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 154.49 | $234.64 | $36,250.15 |
DisclosureSEC source: 0001415889-25-000538 · form4-01032025_100141.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,585.79 F1 · balance_after: Includes 4.41 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:04 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 143.83 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000538 · form4-01032025_100141.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,426.89 Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:37 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 142.53 | $254.34 | $36,250.65 |
DisclosureSEC source: 0001415889-24-024420 · form4-10022024_081006.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,283.06 F1 · balance_after: Includes 4.02 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:37 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 132.7 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024420 · form4-10022024_081006.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,136.51 Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $59.64 | $0.00 |
DisclosureSEC source: 0001127602-24-021894 · form4.xml · derivative · entry 5 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,732 | $0.00 Strike: $59.64 | $0.00 |
DisclosureSEC source: 0001127602-24-021894 · form4.xml · derivative · entry 4 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 30,732 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 6,000 | $59.64 | $357,840.00 |
DisclosureSEC source: 0001127602-24-021894 · form4.xml · nonDerivative · entry 3 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,898.1245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 30,732 | $304.71 | $9,364,409.18 |
DisclosureSEC source: 0001127602-24-021894 · form4.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,898.1245 F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. F2 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 30,732 | $59.64 | $1,832,856.48 |
DisclosureSEC source: 0001127602-24-021894 · form4.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,640.1245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:49 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 144.41 | $238.84 | $34,490.88 |
DisclosureSEC source: 0001415889-24-018933 · form4-07022024_080740.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,003.81 F1 · balance_after: Includes 3.70 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:49 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 141.31 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018933 · form4-07022024_080740.xml · nonDerivative · entry 1 Green Eric Mark · CIK 0001336007 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,855.7 Read SEC document |
| May 07, 2024 Filed May 9, 2024 19:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $59.64 | $0.00 |
DisclosureSEC source: 0001127602-24-014765 · form4.xml · derivative · entry 11 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,732 Underlying: Common Stock · 9,000 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 9, 2024 19:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 41,000 | $0.00 Strike: $59.64 | $0.00 |
DisclosureSEC source: 0001127602-24-014765 · form4.xml · derivative · entry 10 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,732 Underlying: Common Stock · 41,000 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 9, 2024 19:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,684 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001127602-24-014765 · form4.xml · derivative · entry 9 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,684 shares Expires 2025-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 9, 2024 19:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,316 | $0.00 Strike: $57.38 | $0.00 |
DisclosureSEC source: 0001127602-24-014765 · form4.xml · derivative · entry 8 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,316 shares Expires 2025-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2024 Filed May 9, 2024 19:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 9,000 | $59.64 | $536,760.00 |
DisclosureSEC source: 0001127602-24-014765 · form4.xml · nonDerivative · entry 7 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,908.1245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. Read SEC document |
| May 07, 2024 Filed May 9, 2024 19:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 41,000 | $366.65 | $15,032,736.10 |
DisclosureSEC source: 0001127602-24-014765 · form4.xml · nonDerivative · entry 6 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,908.1245 F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. F2 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| May 07, 2024 Filed May 9, 2024 19:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 15,684 | $366.66 | $5,750,678.19 |
DisclosureSEC source: 0001127602-24-014765 · form4.xml · nonDerivative · entry 5 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,908.1245 F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. F2 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| May 07, 2024 Filed May 9, 2024 19:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 9,316 | $366.64 | $3,415,635.94 |
DisclosureSEC source: 0001127602-24-014765 · form4.xml · nonDerivative · entry 4 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,952.1245 F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. F2 · price: The price reported in Column 4 is a weighted average price. Read SEC document |
| May 07, 2024 Filed May 9, 2024 19:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 41,000 | $59.64 | $2,445,240.00 |
DisclosureSEC source: 0001127602-24-014765 · form4.xml · nonDerivative · entry 3 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,908.1245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. Read SEC document |
| May 07, 2024 Filed May 9, 2024 19:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 15,684 | $57.38 | $899,947.92 |
DisclosureSEC source: 0001127602-24-014765 · form4.xml · nonDerivative · entry 2 Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,908.1245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.